Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein – 21 August 2022
Jingxuan Shan, André Megarbane, Aziz Chouchane, Deepak Karthik, Ramzi Temanni, Atilio Reyes Romero, Huiying Hua, Chun Pan, Xixi Chen, Murugan Subramanian, Chadi Saad, Hamdi Mbarek, Cybel Mehawej, Eliane Chouery, Sirin W. Abuaqel, Alexander Dömling, Sami Remadi, Cesar Yaghi, Pu Li, Lotfi Chouchane – 20 August 2022
Hannah M. Lee, Steven D. Lidofsky, Tamar H. Taddei, Lisa J. Townshend‐Bulson – 20 August 2022 – As the third most common cause of cancer‐related death worldwide with significant mortality rates in the United States, hepatocellular carcinoma has strong association with cirrhosis and chronic hepatitis B virus (HBV) with a growing at‐risk population from the rise in chronic liver disease from alcohol use and nonalcoholic fatty liver disease.
Wenhao Luo, Yawen Wang, Ye Li, Taiping Zhang – 20 August 2022
Prowpanga Udompap, Terry M. Therneau, Rachel E. Canning, Joanne T. Benson, Alina M. Allen – 20 August 2022
Jane Chungyoon Kim, Suk Kyun Hong, Kwang‐Woong Lee, Sola Lee, Sanggyun Suh, Su young Hong, Eui Soo Han, YoungRok Choi, Nam‐Joon Yi, Kyung‐Suk Suh – 20 August 2022 – In recent years, laparoscopic techniques for liver resection or living donor hepatectomy have become common surgical methods. However, reports on laparoscopic surgeries for recipients are lacking. Our center has launched the minimally invasive living donor liver transplantation (LDLT) program in March 2020, which is led by two surgeons who are experienced in laparoscopic surgeries.
Chen Zong, Yan Meng, Fei Ye, Xue Yang, Rong Li, Jinghua Jiang, Qiudong Zhao, Lu Gao, Zhipeng Han, Lixin Wei – 20 August 2022
Romain Donne, Amaia Lujambio – 20 August 2022 – The liver is the sixth most common site of primary cancer in humans and the fourth leading cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for 90% of liver cancers. HCC is a prevalent disease with a progression that is modulated by the immune system. Half of the patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib, as a first‐line therapy.
Marina Serper, David E. Kaplan, Tamar H. Taddei, Elliot B. Tapper, Jordana B. Cohen, Nadim Mahmud – 18 August 2022
Alix Demory, Jean‐Marie Péron, Julien Calderaro, Janick Selves, Fatima‐Zohra Mokrane, Giuliana Amaddeo, Valérie Paradis, Marianne Ziol, Olivier Sutter, Lorraine Blaise, Nathalie Ganne‐Carrié, Valérie Vilgrain, François Cauchy, Jessica Zucman‐Rossi, Maxime Ronot, Jean‐Charles Nault – 17 August 2022